| |
 |
|
|
IntellaTurn's Weekly Scoop
By Erin at IntellaTurn ● Nov 19, 2026
What we’re reading: Drug approval firsts | More notable approvals | Around the industry | Heidi Overton’s failed confirmation
|
| |
|
Source: iStock / iQoncept
✅ Sanofi’s INFILBRAY: First treatment of neurological symptoms in rare metabolic disease
-
The FDA signed off on Sanofi’s oral drug Infilbray (venglustat) to treat patients with type 3 Gaucher disease over a certain weight.
-
The once-daily pill is the first medicine that targets the neurological symptoms of the disease, according to the FDA’s announcement of the approval Wednesday evening.
-
Type 3 Gaucher disease (GD3) is a rare disorder driven by a deficiency in a certain enzyme, leading to the toxic buildup of a specific lipid inside cells.
-
Sanofi already has one approved therapy that addresses the systemic but not neurological manifestations of GD3: the ERT Cerezyme. The company also owns the enzyme inhibitor Cerdelga, which is indicated for a different type of Gaucher disease. (BioSpace)
✅ Roche’s GAZYVA: Expanded approval as first treatment for primary membranous nephropathy
-
As Roche’s Gazyva comes under pressure in blood cancer, the anti-CD20 antibody keeps expanding its reach in autoimmune diseases.
-
In its third US indication for an immune-mediated condition, Gazyva has become the first FDA-approved treatment for primary membranous nephropathy (pMN), a rare disease where the immune system mistakenly attacks the tiny filtering units in the kidneys.
-
The drug is specifically approved to reduce proteinuria, or the abnormal presence of protein in the urine, which is a key indicator of kidney damage.
-
Besides pMN, Gazyva is also cleared for certain blood cancers, active lupus nephritis and idiopathic nephrotic syndrome, and it’s awaiting an FDA decision by Dec. 4 for what could be its fourth immune indication, systemic lupus erythematosus. (FiercePharma)
✅ Beren’s LEMBAZ: First drug to help patients with infantile-onset Niemann-Pick disease type C live longer
-
US regulators approved Beren Therapeutics' Lembaz (adrabetadex) on Tuesday, making it the first treatment shown to improve survival in patients with infantile-onset Niemann-Pick disease type C (NPC), according to the company.
-
The approval covers adults and children weighing at least 7 kg whose neurological symptoms began before age six, with the cyclodextrin-based medicine intended to address the underlying cholesterol-trafficking defect that drives the rare neurodegenerative disorder.
-
The FDA noted that although two other therapies, Zevra Therapeutics' Miplyffa (arimoclomol) and IntraBio's Aqneursa (levacetylleucine), were previously approved for NPC, neither had been shown to reduce the risk of death.
-
Lembaz is administered by intrathecal injection every two weeks and carries a boxed warning for hearing impairment, including permanent hearing loss. (Firstword)
|
| |
|
More notable drug approvals
Source: iStock
✅ Roche’s WILSERDLY: New breast cancer drug and treatment option for some patients
-
The FDA on Monday approved a new breast cancer drug from Roche, teeing up the launch of a medicine that the Swiss company has said could become its top-selling product ever.
-
The approval of Wilserdly (giredestrant) was one of the most important regulatory decisions Roche had been awaiting.
-
It also gives the company another foothold in breast cancer treatments, a field in which it has a storied history with the drug Herceptin through its subsidiary Genentech, though in recent years it’s fallen behind rival pharma companies in oncology.
-
The approval is specifically for patients with HR-positive, HER2-negative advanced breast cancer that has picked up a mutation in the ESR1 gene, a sign that the tumor is developing resistance to standard treatments. (STAT)
✅ AstraZeneca’s INFIMZI: Perioperative combination therapy expands MIBC treatment options
-
The FDA approved Imfinzi (durvalumab) in combination with Padcev (enfortumab vedotin-ejfv) for adults with muscle-invasive bladder cancer (MIBC) who are not eligible for, or who decline, cisplatin-based chemotherapy.
-
Under the approval, announced last Friday, patients receive Imfinzi and Padcev together before radical cystectomy, a surgery to remove the bladder.
-
After surgery, they continue on Imfinzi alone. (Cure Today)
✅ GSK's NELKARMI: Accelerated approval for new treatment of lung cancer
-
The FDA granted accelerated approval to GSK’s Nelkarmi (neladalkib) for the treatment of adults with locally advanced or metastatic anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) who have previously received the following therapy in the unresectable locally advanced or metastatic setting: one prior ALK tyrosine kinase inhibitor (TKI) consisting of alectinib, or two or more prior ALK TKIs and platinum-based chemotherapy.
-
The UK pharma noted this approval comes ahead of the original FDA target action date of November 27, 2026 and follows the FDA's Breakthrough Therapy and Orphan Drug designations. (Pharma Letter)
|
| |
|
Source: Axios Visuals
➡️ Summit shares fall as FDA rejects closely watched PD-1/VEGF drug
-
The FDA rejected a closely watched cancer drug from Akeso and Summit Therapeutics, arguing that the therapy needed to extend patients’ lives in clinical testing to earn an approval.
-
US regulators determined that the ability of ivonescimab to help delay tumor progression in a late-stage study in lung cancer wasn’t, on its own, enough to “support a positive benefit-risk profile,” according to a statement.
-
Summit asked the FDA to approve a combination of ivonescimab and chemotherapy in people with EGFR-mutated, non-small cell lung cancer.
-
In the “HARMONi” study, the company tested that combination against chemotherapy alone in people whose disease had progressed following treatment with a targeted therapy.
-
But while Summit found that the ivonescimab-chemo regimen slowed disease progression or death by more than two months, it also reported that the combination didn’t clearly lengthen lives upon a primary trial analysis. (Biopharma Dive)
➡️ Lilly's 14th acquisition of the year is a little-known blood cancer biotech
-
Eli Lilly has been on a shopping spree this year thanks to its GLP-1-driven revenue, and its 14th acquisition of 2026 is in cancer, the domain of expertise for the pharma’s head dealmaker.
-
On Monday, Calytrix Bio said Indianapolis-based Lilly will pay as much as $1.5 billion to acquire it. The biotech, which is doing work in oncology, was formed last year by JP Morgan’s life sciences investment team and Westlake BioPartners.
-
It has raised a Series A from those firms, followed by a Series B of undisclosed size led by Avoro Ventures, according to a press release.
-
The startup has a preclinical candidate for mutant calreticulin (mCALR)-driven essential thrombocythemia and myelofibrosis. The drug is a biparatopic antibody that targets both type 1 and type 2 mCALR. Both of the hematologic cancers originate in the bone marrow. (Endpoints)
|
| |
|
Interesting read: How FDA nominee Heidi Overton’s confirmation failed
Source: Axios Visuals
Setting the stage: It was less than 24 hours before the Trump administration’s FDA nominee Heidi Overton would face a crucial vote by the Senate HELP Committee.
-
It was going to be close. But Overton’s team had reason to be hopeful.
-
While the committee’s Chairman Bill Cassidy (R-LA) hadn’t publicly committed to backing her, he was working his colleagues behind the scenes to shore up support.
-
Overton’s handlers, whose job it was to guide her through the Senate, believed that those efforts would deliver the votes.
Instead, a few hours later, Overton’s nomination was dead, part of a coordinated campaign that included President Trump’s new Chief of Staff Stephen Miller.
Overton’s team was blindsided, with one member finding out from a journalist that the White House had pulled her candidacy.
A contact texted Cassidy, “I thought she had the votes.” “So did I,” Cassidy wrote back.
Soon after, Cassidy put out a social media post saying that the White House had “abandoned a viable confirmation path for Dr. Overton. The WH said that this was because she did not have the votes to pass. This was odd as I was having productive conversations with members.”
Why it matters: With Overton’s chances finished and Democrats set to take control of the Senate, the FDA is likely looking at a long period without a permanent leader.
Continue reading: Endpoints
|
| |
|
✨ Thanks for reading! ✨
🌐 About us: IntellaTurn, LLC delivers business-critical and timely information to biopharmaceutical companies and start-ups in the life sciences industry.
📧 Questions? If you liked this, but need more tailored business insights, get in touch about our curated daily, weekly, and bi-weekly newsletters.
|
| |
|
|
|
|
|
|
|